Skip to main content
. Author manuscript; available in PMC: 2013 May 22.
Published in final edited form as: J Am Geriatr Soc. 2010 Jan 8;58(2):292–299. doi: 10.1111/j.1532-5415.2009.02673.x

Figure 1.

Figure 1

Event rate of new fractures in patients receiving zoledronic acid (ZOL) 5 mg once yearly and those receiving placebo at 1 and 3 years. *Hazard ratio (HR) (95% confidence interval) of ZOL versus placebo computed from the Cox proportional hazards regression model stratified according to study with treatment as a factor within the subgroup. Event rate calculated from Kaplan-Meier estimates.